Abstract
Background: Use of natural agents is an upcoming area of research in cancer biology. Caffeic acid phenethyl ester (CAPE) has received great attention because of its therapeutic potential in various conditions including cancer. It is an active/abundant component of propolis, a honey bee hive product produced by bees using their enzyme-rich digestive secretions on resinous mix, bee wax and pollen from plants. It is used to protect the beehive against bacteria and other infections. Therefore a literature survey was done to understand the therapeutic potential of this compound. Although a lot of work has been done on chemotherapeutic aspects of CAPE and many reviews were available, yet its role as a radiomodulator was not clear.
Objective: The objective of the review was to collect data on role of Caffeic acid phenethyl ester as radioprotector and /or sensitizer to evaluate its potential as modulator of radiation effects during cancer therapy.
Methods: For literature survey, Pubmed and Google search engines were used. Data were collected up to August 2017. PubMed advanced search builder showed 845 papers on CAPE. This search was further narrowed down to synthesis, bioavailability, CAPE derivatives, radioprotective and radiosensitizing effects of CAPE.
Results: This review focused on the differential radiomodulatory effects of CAPE in normal and cancer cells. Besides chemistry and bioavailability, it’s potential as a therapeutic agent against radiation induced damage was also evaluated.
Conclusion: CAPE was found to act both as radioprotector and radiosensitizer. Depending on the tissue type it can modulate the radiation response by following different mechanisms.
Keywords: Propolis, CAPE, radiation, radioprotection, radiosensitization, cancer.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Radio-Modulatory Potential of Caffeic Acid Phenethyl Ester: A Therapeutic Perspective
Volume: 18 Issue: 4
Author(s): Km Anjaly and Ashu B. Tiku*
Affiliation:
- Radiation and Cancer Therapeutics Lab, School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067,India
Keywords: Propolis, CAPE, radiation, radioprotection, radiosensitization, cancer.
Abstract: Background: Use of natural agents is an upcoming area of research in cancer biology. Caffeic acid phenethyl ester (CAPE) has received great attention because of its therapeutic potential in various conditions including cancer. It is an active/abundant component of propolis, a honey bee hive product produced by bees using their enzyme-rich digestive secretions on resinous mix, bee wax and pollen from plants. It is used to protect the beehive against bacteria and other infections. Therefore a literature survey was done to understand the therapeutic potential of this compound. Although a lot of work has been done on chemotherapeutic aspects of CAPE and many reviews were available, yet its role as a radiomodulator was not clear.
Objective: The objective of the review was to collect data on role of Caffeic acid phenethyl ester as radioprotector and /or sensitizer to evaluate its potential as modulator of radiation effects during cancer therapy.
Methods: For literature survey, Pubmed and Google search engines were used. Data were collected up to August 2017. PubMed advanced search builder showed 845 papers on CAPE. This search was further narrowed down to synthesis, bioavailability, CAPE derivatives, radioprotective and radiosensitizing effects of CAPE.
Results: This review focused on the differential radiomodulatory effects of CAPE in normal and cancer cells. Besides chemistry and bioavailability, it’s potential as a therapeutic agent against radiation induced damage was also evaluated.
Conclusion: CAPE was found to act both as radioprotector and radiosensitizer. Depending on the tissue type it can modulate the radiation response by following different mechanisms.
Export Options
About this article
Cite this article as:
Anjaly Km and Tiku B. Ashu *, Radio-Modulatory Potential of Caffeic Acid Phenethyl Ester: A Therapeutic Perspective, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (4) . https://dx.doi.org/10.2174/1871520617666171113143945
DOI https://dx.doi.org/10.2174/1871520617666171113143945 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Edelfosine: An Antitumor Drug Prototype
Anti-Cancer Agents in Medicinal Chemistry Immunomodulating and Anti-Allergic Effects of Negroamaro and Koshu Vitis vinifera Fermented Grape Marc (FGM)
Current Pharmaceutical Design Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer
Current Cancer Drug Targets VEGF Signaling in Cancer Treatment
Current Pharmaceutical Design Lysophosphatidic Acid and Renal Fibrosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Targeting Epigenome As An Innovative Pharmacological Strategy For Castration-resistant Prostate Cancer
Clinical Cancer Drugs The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells
Current Cancer Therapy Reviews Editorial [Hot topic: Imaging Agents for Apoptosis (Guest Editor: Wenbin Zeng)]
Anti-Cancer Agents in Medicinal Chemistry Zinc, Metallothioneins and Longevity: Interrelationships with Niacin and Selenium
Current Pharmaceutical Design Application of Carbon Nanomaterials in Gene Delivery for Endogenous RNA Interference <i>In Vitro</i> and <i>In Vivo</i>
Current Pharmaceutical Design Estrogen in Prostate Cancer - Friend or Foe?
Current Cancer Therapy Reviews Low Activity of Plasminogen Activator: A Common Feature of Non- Iatrogenic Comorbidities of Schizophrenia
CNS & Neurological Disorders - Drug Targets Structural Bases for Substrate and Inhibitor Recognition by Matrix Metalloproteinases
Current Medicinal Chemistry Meet Our Editorial Board Member:
Reviews on Recent Clinical Trials Potentials and Challenges of Active Targeting at the Tumor Cells by Engineered Polymeric Nanoparticles
Current Pharmaceutical Biotechnology DNA Base Excision Repair: The Achilles' Heel of Tumour Cells and their Microenvironment?
Current Pharmaceutical Design Isothiocyanates in the Chemoprevention of Bladder Cancer
Current Drug Metabolism Analysis of Glycosylation and Other Post-Translational Modifications by Mass Spectrometry
Current Analytical Chemistry Editorial [Hot Topic: The Endothelin System: Vascular Targets for Therapy in Disease (Guest Editor: Michael R. Dashwood)]
Current Vascular Pharmacology Muscarinic Receptors as Targets for Metronomic Therapy in Breast Cancer
Current Pharmaceutical Design